Evidence supporting the use of: Docosapentaenoic acid
For the health condition: Psoriasis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Docosapentaenoic acid (DPA), an omega-3 polyunsaturated fatty acid found in fish oil and some plant sources, has been researched for its potential anti-inflammatory properties. Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferation of keratinocytes and immune dysregulation. Omega-3 fatty acids, particularly EPA and DHA, have been studied more extensively for their role in modulating inflammation and, by extension, for their potential benefit in psoriasis management.

DPA is a metabolic intermediate between EPA and DHA and shares some biological activities with them, though it has been less frequently studied. There is emerging but limited evidence that DPA, like other omega-3s, may help reduce inflammation by influencing eicosanoid production, cytokine release, and immune cell activity. However, most clinical trials and meta-analyses focus on EPA and DHA, with DPA often included as a minor component or not analyzed separately.

Some in vitro and animal studies suggest that DPA may exert anti-inflammatory effects relevant to psoriasis, but robust clinical trials specifically evaluating DPA supplementation in psoriasis patients are lacking. Any benefits attributed to DPA for psoriasis are therefore extrapolated from broader research on omega-3 fatty acids. Current guidelines and reviews generally note a modest benefit of omega-3 supplementation for psoriasis, but do not specifically endorse DPA due to insufficient direct evidence. Thus, while there is a scientific rationale and some preliminary evidence, the direct support for DPA in psoriasis is limited.

More about Docosapentaenoic acid
More about Psoriasis

Products containing Docosapentaenoic acid

We currently have no products on Vitabase that contain this ingredient.